Eli Lilly reported top-line Phase 3 results for retatrutide in obesity, describing weight loss outcomes up to 28% at the highest tested doses over 80 weeks. The company also said the dataset shows significant improvements in cardiovascular risk factors, while disclosing a side-effect profile that includes nausea, diarrhea, constipation, and vomiting. The program focuses on retatrutide’s “triple-G” mechanism targeting GIP, GLP-1, and glucagon receptors, aiming to broaden efficacy versus existing GLP-1-based options. Lilly said more detailed results are expected for upcoming scientific meetings. The readout adds to competitive pressure in obesity drug development as sponsors compare durability, tolerability, and endpoint tradeoffs ahead of potential regulatory submissions and label strategies.